What is Cyanotech?
Cyanotech operates as a premier developer and manufacturer of high-quality microalgae-based nutritional ingredients. By leveraging proprietary cultivation technology at its 96-acre Kona site, the company produces flagship brands such as BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica. These products serve a diverse client base, ranging from direct-to-consumer retail channels to large-scale nutraceutical and cosmeceutical manufacturers. As a leader in the health and wellness sector, Cyanotech maintains rigorous quality standards, ensuring its offerings are Generally Recognized as Safe (GRAS) by the FDA, thereby reinforcing its reputation for purity and efficacy in the global dietary supplement market.
How much funding has Cyanotech raised?
Cyanotech has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Cyanotech
PPP
Public-Private Partnership
What's next for Cyanotech?
Looking ahead, the infusion of capital is expected to catalyze Cyanotech's strategic growth initiatives, particularly in the optimization of its patented microalgae production processes. By focusing on operational efficiency and market penetration, the company is well-positioned to capitalize on the rising consumer demand for natural, science-backed health solutions. Future efforts will likely prioritize the expansion of its digital footprint via Nutrex-Hawaii and the strengthening of its distribution networks to meet the evolving needs of the global wellness industry. This financial backing serves as a cornerstone for long-term value creation and sustained innovation in the microalgae technology space.
See full Cyanotech company page
